The interaction between the Wnt/β-catenin signaling cascade and PKG activation in cancer

Kevin Lee, Gary A Piazza

Drug Discovery Research Center, Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604-1405, USA.

Abstract

The activation of the Wnt/β-catenin signaling cascade has been well studied and documented in colorectal cancer (CRC). The long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) has been shown to reduce the incidence and risk of death from CRC in numerous epidemiological studies. The NSAID sulindac has also been reported to cause regression of precancerous adenomas in individuals with familial adenomatous polyposis who are at high risk of developing CRC. The mechanism responsible for cancer chemopreventive activity of NSAIDs is not well understood but may be unrelated to their cyclooxygenase inhibitory activity. Emerging evidence suggests that sulindac inhibits the growth of colon tumor cells by suppressing the activity of certain phosphodiesterase isozymes to activate cGMP-dependent protein kinase, PKG, through the elevation of the second messenger cyclic guanosine monophosphate, cGMP. PKG activation has been shown to inhibit the nuclear translocation of β-catenin, reduce β-catenin mRNA and protein levels, and suppress the transcriptional activity of β-catenin. This review describes the relationship between the Wnt/β-catenin signaling cascade and the activation of PKG through PDE inhibition and elevation of intracellular cGMP levels.

Keywords: Wnt, β-catenin, PKG, cGMP, PDE, NSAID, colon cancer, breast cancer

Introduction

Colorectal cancer (CRC) is the third most common type of cancer among men and women in the United States. It is estimated that over 71,000 men and 65,000 women were diagnosed with CRC and over 26,000 men and 24,000 women died of this malignancy in 2014[1]. CRC is a disease that can take decades to develop in humans that requires sequential genetic mutations to tumor suppressor or oncogenes, including APC, KRAS, PIK3CA, SMAD4, and TP53[2]. Even though early detection procedures have been shown to decrease mortality and incidence of CRC, there is an unmet medical need for safe and effective drugs to use for CRC for chemoprevention, especially in individuals at high risk of developing CRC[3].

The Wnt proteins constitute a major family of proteins that are involved in many biologic processes including proliferation as well as embryological development[3]. Once Wnt is translated, it is further processed by the endoplasmic reticulum (ER) and the Golgi to be secreted into the extracellular space[4]. In the extracellular environment, Wnt can then participate in short range paracrine signaling where it binds the Frizzled

*Corresponding author: Kevin Lee, Drug Discovery Research Center, Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604-1405, USA. Tel: 1-251-445-9885, E-mail: kjlee@health.southalabama.edu.
Received 25 October 2016, Accepted 28 November 2016, Epub 29 December 2016

© 2017 by the Journal of Biomedical Research. All rights reserved.

CLC number: R458, Document code: A
The authors reported no conflict of interests.
This is an open access article under the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited.

doi:10.7555/JBR.31.20160133
receptor on nearby cell membranes\cite{5}. Under conditions in which Wnt is absent, \(\beta\)-catenin that is not bound at cadherin junctions (free \(\beta\)-catenin) associates with adenomatous polyposis coli (APC), Axin, and glycogen synthase kinase 3\(\beta\) (GSK3\(\beta\)) in a complex known as the destruction complex. Upon association with the destruction complex, GSK3\(\beta\) phosphorylates \(\beta\)-catenin\cite{6}, thus priming it for ubiquitination by \(\beta\)-TRCP and degradation by the proteasome\cite{7}. Wnt binding to Frizzled and its co-receptor, low-density lipoprotein receptor-related protein (LRP), induces phosphorylation of Dishevelled (Dvl)\cite{8}. Phosphorylated Dvl then associates with Axin, inducing dissociation of the \(\beta\)-catenin destruction complex. Free \(\beta\)-catenin then accumulates in the cytoplasm of the cell and is translocated to the nucleus. Once in the nucleus \(\beta\)-catenin binds to T cell factor/lymphoid-enhancer factor (Tcf/Lef) transcription factors and activates the transcription of several target genes, which can include c-Myc, cyclin D1, gastrin, and ITF-2 (Fig. 1)\cite{9-14}.

**Disregulation of Wnt signaling in cancer**

 Genetic mutations in components that make up the Wnt signaling pathway can occur in as much as 80% of CRC\cite{15}. Disruptions in the \(\beta\)-catenin destruction complex can result in activation of the Wnt signaling pathway that could lead to aberrant signaling through the Tcf/Lef transcription factors. APC has been shown to act as a tumor suppressor whereby it is known to suppress cytoplasmic and nuclear levels of \(\beta\)-catenin in CRC cells\cite{16}. Indeed, APC has been referred to as one of the gatekeepers of colorectal tumorigenesis\cite{2}. Studies have shown that mutations yielding a truncated APC protein are responsible for patients with familial adenomatous polyposis (FAP). A mouse model has been shown to harbor a single T-A transversion at codon 850 in the APC gene which results in a nonsense mutation\cite{17}. It should be noted that mice with a homozygous loss of APC do not survive through the early stages of embryonic development\cite{18}. These mice, known as \(APC^{min/+}\) mice (multiple intestinal neoplasia) develop spontaneous tumors throughout the small intestine and the colon, and has been used as a useful tool in the study of CRC. Inbreeding of a single mouse containing a large number of colorectal tumors has yielded a strain that produces large amounts of colorectal tumors thereby improving their usefulness as a mouse model in the study of CRC and for assessing the efficacy of chemopreventive drugs for CRC\cite{19}.

Mutations in other components of the Wnt signaling pathway have also been shown to play a role in colon tumorigenesis. Mutations at the GSK3\(\beta\) regulatory sites in the \(\beta\)-catenin gene, \(CTNNB1\), prevents phosphorylation by GSK3\(\beta\), thereby allowing \(\beta\)-catenin to bypass the destruction complex\cite{20-22}. These stabilizing muta-

---

**Fig. 1  Wnt signaling.** In the off state, \(\beta\)-catenin is bound by the destruction complex, phosphorylated, ubiquitinated, and degraded. The presence of Wnt causes phosphorylation of disheveled by LRP, and this recruits axin which disrupts the \(\beta\)-catenin destruction complex, thereby allowing \(\beta\)-catenin accumulation and translocation to the nucleus. In the nucleus, \(\beta\)-catenin binds to Tcf/Lef transcription factors to induce transcription of target genes.
tions induces an increase in β-catenin protein expression in humans\(^{23}\). In addition, a mutation in GSK3β has been shown to inhibit its ability to phosphorylate substrates, thereby allowing β-catenin to accumulate in the cells\(^{24}\).

**NSAIDs in cancer**

Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed to treat inflammatory conditions and are well known to inhibit cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) and suppress prostaglandin synthesis. Epidemiological studies have linked NSAIDs to a decrease in the incidence and the mortality rate of CRC as well as other malignancies\(^{25}\). The NSAID, sulindac has been shown to reduce the number of colorectal polyps as well as their mean diameter in patients with FAP, which is characterized by the formation of hundreds of adenomas that have the potential to develop into adenocarcinomas\(^{26}\). In \(APC^{min/}\) mice, sulindac significantly reduced the incidence of intestinal adenomas\(^{27}\). A metabolite of sulindac, sulindac sulfone, was also shown to inhibit tumorigenesis in the azoxymethane-induced rat model of colon tumorigenesis\(^{28}\).

Sulindac can be metabolized by the liver into a sulfone metabolite through oxidation or into a sulfinic metabolite through bioreduction involving colonic bacteria\(^{29}\). Reduction into sulindac sulfide is reversible and this metabolite is responsible for the anti-inflammatory mechanism of sulindac, while the sulfone metabolite lacks anti-inflammatory activity and does not inhibit cyclooxygenase. Interestingly, both sulindac sulfide and sulfone have been shown to inhibit tumor cell growth in vitro\(^{28}\), while sulindac sulfone shows similar anticancer activity as sulindac in rodent models of chemical-induced tumorigenesis\(^{28}\). This suggests that a cyclooxygenase-independent mechanism is responsible for the cancer chemopreventive activity of sulindac, and possibly other NSAIDs. Sulindac sulfone was shown to be effective in clinical trials for individuals with FAP but was not approved by the FDA, likely attributed to low potency and a narrow therapeutic window in which hepatotoxicity was the dose-limiting toxicity\(^{30}\).

**Phosphodiesterase implications in cancer**

Cyclic nucleotide degrading assays were first used to show that sulindac sulfone inhibits phosphodiesterase (PDE) activity at concentrations equivalent to those required to inhibit colon tumor cell growth\(^{31}\). Cyclic nucleotides are generated by enzymes known as cyclases that use GTP or ATP to generate cyclic-GMP or cyclic-AMP, respectively. The cyclic nucleotides are then hydrolyzed into 5′GMP or 5′AMP through the action of phosphodiesterases in which inhibitors can cause a transient or sustained elevation of intracellular cGMP or cAMP levels, respectively. There are currently 11 known families of PDE’s that contain over 50 different isoforms or splice variants\(^{32}\). Phosphodiesterases 5, 6, and 9 are cGMP specific, meaning that they selectively act to hydrolyze cGMP into 5′GMP\(^{32}\). Phosphodiesterases 4, 7, and 8 are cAMP specific, meaning that they selectively hydrolyze cAMP into 5′AMP\(^{32}\). PDEs 1, 2, 3, 10, and 11 are dual substrate PDEs, meaning that they can hydrolyze both cGMP and cAMP into 5′GMP and 5′AMP, respectively\(^{32}\). Cyclic nucleotides can act as second messenger molecules in signaling pathways by activating protein kinases or other biochemical processes, including ion channels or regulating other PDE isozymes. In the case of protein kinases, cGMP can bind to and activate cyclic GMP-dependent protein kinase (PKG), while cyclic AMP can bind and activate cAMP-dependent protein kinase (PKA)\(^{33}\). Cyclic nucleotides can also influence nucleotide-gated ion channels, or bind to certain cyclic nucleotide dependent PDEs resulting in their activation\(^{33}\). There is also a level of crosstalk between cGMP and cAMP whereby the levels of cGMP can act to regulate the levels of cAMP through PDE activation or inhibition\(^{34}\). It has also been shown that cAMP can activate PKG in coronary myocytes, thereby introducing another level of cyclic nucleotide cross-activation\(^{35}\).

Cyclic nucleotide elevation through PDE inhibition was shown to inhibit tumor cell growth in multiple cancer cell lines\(^{11,36-38}\). In those same studies, it was shown that certain PDEs (PDE5, and PDE10) were expressed in high levels in tumor cells when compared to normal cells of the same tissue origin and that when these phosphodiesterases were inhibited through either pharmacological mechanisms or through genetic silencing, cyclic nucleotide levels were increased leading to activation of protein kinases, PKG and PKA. Sulindac was shown in these studies to inhibit tumor cells through a cyclooxygenase-independent mechanism of cGMP PDE inhibition which led to the elevation of cGMP and thus the activation of PKG. It has also been shown that inhibition of PDE9 induced an increase in the concentration of intracellular cGMP in estrogen receptor (ER) positive breast cancer cell lines (MCF-7) as well as in ER negative breast cancer cell lines (MDA-MB-468)\(^{39}\). However, the authors did not determine any downstream targets other than caspase activation and subsequent apoptosis\(^{39}\). It has also been shown...
that a PDE2 selective inhibitor induced cGMP elevation and attenuated UVB-induced carcinogenesis in mice[40]. Patients with chronic lymphocytic leukemia (CLL) were shown to have an increase in PDE7B expression[41]. Cells isolated from these patients underwent apoptosis when treated with a PDE7 inhibitor, albeit through an increase in cAMP[41]. PDE10 was shown to be inhibited through the highly selective PDE10 inhibitor, PF-2545920 (MP-10), which also led to the elevation of cGMP and the activation of PKG in colon cancer cell lines[11-12]. The increase in activity of PKG was shown to have an effect on β-catenin signaling and thus initiation of apoptosis[11-12,37-38,42-44].

**Interaction of PKG and the Wnt signaling cascade**

PKG is a kinase that phosphorylates specific proteins depending on the intracellular level of cGMP. PKG is encoded by two distinct genes in eukaryotes; **prkg1** encodes PKG-I while **prkg2** encodes PKG-II. PKG-I further exists in two isoforms based on alternative splicing, PKG-Iα and PKG-Iβ. PKG consists of an N terminus comprised of a leucine zipper and an auto-inhibitory domain, a regulatory domain, and a c catalytic domain which binds ATP to catalyze phosphate transfer to target molecules[45]. Both PKG-Iα and PKG-Iβ are found in vascular smooth muscle cells, the uterus, gastrointestinal tract, kidney, and trachea where they play a role in smooth muscle relaxation[46]. In the intestinal tract, PKG-II is involved in the activation of the cystic fibrosis transmembrane regulator (CFTR) anion channel and chloride channels (CIC), causing the efflux of chloride and bicarbonate. Water is then effluxed into the intestinal lumen[47]. Upon binding of cGMP to the regulatory domain, the auto-inhibitory domain of PKG is released allowing binding of ATP in the catalytic domain and subsequent phosphorylation of target proteins. PDEs therefore can regulate the activity of PKG due to their relative abundance or activity in cells, where high PDE levels or activity would keep cyclic nucleotides at low levels, while suppression of PDE levels or activity can increase the levels of cyclic nucleotides and activate protein kinases such as PKG or other downstream mediators.

Ectopic expression of PKG-I was shown to induce apoptosis and reduce cell migration of colon tumor cells[44]. These studies showed that expression of constitutively active forms of PKG-Iα, as well as PKG-Iβ reduced colony formation in SW-480 colon tumor cells. The authors also reported that overexpression of PKG-Iβ caused a reduction in levels of cyclin D1, as well as β-catenin and at the same time observed an increase in levels of p21CIP1. In addition, the investigators noted that cyclin D1 was transcriptionally suppressed.

The COX-2 selective inhibitor, celecoxib, was also reported to inhibit the growth of SW-480 colon tumor cells by a COX-independent mechanism involving PDE inhibition[48]. In these studies, celecoxib increased intracellular levels of cGMP and activated PKG as shown by an increase in vasodilator-stimulated phosphoprotein (VASP) phosphorylation[49]. Furthermore, the sulfone metabolite of sulindac (exisulind) was shown to inhibit PDE5 at lower concentrations than those required to inhibit tumor cell growth and induce apoptosis[31]. These same studies also showed that PKG was activated upon treatment with sulindac sulfone, which corresponded with a decrease in β-catenin, as well as a reduction in cyclin D1 levels.

The sulfide metabolite of sulindac was shown to inhibit the growth of breast cancer cell lines and induce apoptosis at the same concentrations by which treatment increased intracellular cGMP levels[36]. This was also accompanied by an increase in the phosphorylation of VASP at serine 239. However, a guanylyl cyclase inhibitor caused an increase in the concentration of sulindac sulfide required to inhibit growth. The authors also noted that treatment with an adenyl cyclase activator, forskolin, had little to no effect on breast tumor cell growth. They concluded that sulindac sulfide, through the inhibition of PDE5, caused cell cycle arrest and induced apoptosis through cGMP elevation, and activation of PKG. It was further shown that sulindac sulfide selectively induced apoptosis in breast tumor cells, while normal mammary epithelial cells were insensitive, through the reductin in nuclear translocation of β-catenin[37]. Silencing of PDE5 by siRNA inhibited the growth of breast tumor cells and suppressed β-catenin levels[37].

Sulindac sulfide was also shown to inhibit the growth of colon tumor cell lines selectively over normal colon epithelial cells as well as an increase in caspase activity and a reduction in proliferation accompanied by an increase in intracellular cGMP[50]. Consistent with a mechanism involving cGMP PDE inhibition, PDE5 was shown to be overexpressed in colon tumor cells compared to normal colon epithelial cells. Upon silencing of PDE5 with siRNA, cell viability was decreased as well as proliferation; conversely, caspase activity was increased. An analog of cGMP, 8-Bromo-cGMP, was used to show that β-catenin levels are reduced, as well as cyclin D1 and survivin, with PKG activation. The reduction in β-catenin in response to sulindac sulfide treatment was shown to be at the transcription level through the use of a Tcf/Lef reporter
assay driving the CTNNB1 promoter. Furthermore, a non-COX inhibitory derivative of sulindac more potently inhibited the growth of colon tumor cell lines than sulindac sulfide. This novel sulindac derivative more potently and selectively inhibited PDE5 over other PDEs and inhibited tumor cell growth through similar mechanisms.

Further research into cGMP PDEs revealed that PDE10 mRNA and protein are overexpressed in colon tumor cell lines compared to normal colon epithelial cells. PDE10 is also overexpressed in human colon tumors and in tumors from APCmin/+ mice relative to normal colon mucosa. PDE10 inhibitors suppressed the proliferation and induced apoptosis of colon tumor cells by a mechanism involving G1 cell cycle arrest. Knockdown of PDE10 yielded similar effects as well as causing a decrease in cyclin D1 and survivin. Other studies implicated β-catenin in the PDE10 signaling pathway by showing that knockdown of PDE10 caused a reduction in β-catenin transcriptional activity using a Tcf/Lef reporter assay. The highly selective and potent PDE10 inhibitor, PF-2545920 (MP-10), was also shown to induce apoptosis through an increase in intracellular cGMP, the activation of PKG, and the reduction of β-catenin translocation to the nucleus.

As previously mentioned, PDE10 is a dual-specific phosphodiesterase capable of hydrolyzing both cGMP and cAMP. Therefore, further studies are necessary to determine if the effects of PDE10 inhibition involve an increase in cGMP or cAMP or an increase in both. Through the use of pharmacological inhibitors of PKG and PKA, recent studies suggest that the anticancer activity resulting from PDE10 inhibition is exclusively through the activity of cGMP/PKG signaling in which the effects on cAMP/PKA signaling may be ancillary. As mentioned previously, the inhibition of the cGMP-specific PDE5 similarly led to a reduction of β-catenin, survivin, cyclin D1 levels, as well as a reduction in Tcf/Lef transcriptional activity. This supports the possibility that the effects of PDE10 inhibition exclusively involve cGMP/PKG signaling. In addition, dual inhibition of PDE5 and PDE10 results in additive or synergistic effects on cGMP/PKG signaling on β-catenin mediated transcriptional activity.

Further evidence suggests that NSAIDs can inhibit Wnt/β-catenin signaling in prostate cancer cell lines. The investigators determined that sulindac sulfide inhibits tumor cell growth through a β-catenin mechanism by utilizing a novel small molecule designed to inhibit the interaction of β-catenin with Tcf/Lef. However, the authors did not investigate if the effects were due to the activation of PKG or through some other mechanism.

Ectopic expression of PKG-Iβ was shown to cause a decrease in transcriptional activity of the CTNNB1 gene causing a decrease in β-catenin expression but not through an increase in degradation. Activation of JNK occurred concomitantly with a decrease in

\[ \text{Fig. 2 Phosphodiesterase activity.} \]

The increased activity of PDEs (left) causes the intracellular concentration of cGMP to remain at low levels, thereby keeping the basal activity of PKG low. This allows β-catenin to translocate to the nucleus. When PDEs are inhibited by small molecules or through genetic silencing, the concentration of cGMP increases. The cyclic nucleotide then binds and activates PKG which inhibits β-catenin mediated signaling.
**CTNNB1** transcription causing an increase in FOXO4 activity. FOXO has been shown to repress Wnt/β-catenin signaling through the decrease in β-catenin transcription in osteosarcoma cells\[^{[54]}\]. This dual role of PKG in regards to a decrease in transcriptional activity has been limited to the PKG-I isoform; therefore, more studies would need to be conducted to determine if these findings translate to PKG-II.

**Discussion**

The Wnt/β-catenin signaling cascade has been implicated in many biologic processes including, but not limited to cell growth, differentiation, development, as well as even cancer. Indeed, the APC protein is one of the best known examples of a tumor suppressor that regulates β-catenin signaling. NSAIDs are known to be effective for the treatment of patients with FAP but are not FDA approved for such a use due to potentially fatal side effects relating to their cyclooxygenase inhibitory activity and suppression of physiologically important prostaglandins. The reduction of incidence of adenomas in *APC*\[^{min/τ}\] mice treated with sulindac suggested that sulindac played a role in modulating Wnt/β-catenin signaling. It was later discovered that the inhibition of PDE5 was responsible for a decrease in Wnt/β-catenin signaling through the activation of PKG. In addition, PDE10 inhibition also resulted in an activation of PKG and a reduction in β-catenin mediated signaling. More research would need to be taken in order to ensure results seen in regard to PDE10 inhibition were due to PKG activation. In summary, the activation of PKG has been shown to modulate the Wnt/β-catenin signaling cascade through the reduction of β-catenin protein levels, blocking the nuclear translocation of β-catenin, decreasing the level of β-catenin transcriptional activity through the Tcf/Lef promoter, decreasing the transcription of β-catenin itself, or through interactions with other transcription factors. A depiction of how PDEs interact with the Wnt/β-catenin signaling cascade is shown in Fig. 2.

However, even though great strides have been made in understanding the role PKG plays in the Wnt/β-catenin signaling cascade, the exact mechanism through which PKG exerts its effects have not yet been fully elucidated. More research into this area will help guide the research community in understanding the role that PKG plays in modulating Wnt/β-catenin signaling.

**References**

\[^{[1]}\] Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014[J]. *CA Cancer J Clin*, 2014, 64(2): 104–117.

\[^{[2]}\] Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes[J]. *Science*, 2013, 339(6127): 1546–1558.

\[^{[3]}\] Binefa G, Rodriguez-Moranta F, Teule A, et al. Colon cancer: from prevention to personalized medicine[J]. *World J Gastroenterol*, 2014, 20(22): 6786–6808.

\[^{[4]}\] Willert K, Nusse R. Wnt proteins[J]. *Cold Spring Harb Perspect Biol*, 2012, 4(9): a007864.

\[^{[5]}\] Clevers H, Nusse R. Wnt/β-catenin signaling and disease[J]. *Cell*, 2012, 149(6): 1192–1205.

\[^{[6]}\] Yost C, Torres M, Miller JR, et al. The axis-inducing activity, stability, and subcellular regulation of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3 [J]. *Genes Dev*, 1996, 10(12): 1443–1454.

\[^{[7]}\] Winston JT, Strack P, Beer-Romero P, et al. The SCFbeta-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkappaBalpha and β-catenin and stimulates IkappaBalpha ubiquitination in vitro[J]. *Genes Dev*, 1999, 13(3): 270–283.

\[^{[8]}\] González-Sancho JM, Greer YE, Abrahams CL, et al. Functional consequences of Wnt-induced dephosphorylated 2 phosporylation in canonical and noncanonical Wnt signaling[J]. *J Biol Chem*, 2013, 288(13): 9428–9437.

\[^{[9]}\] He TC, Sparks AB, Rago C, et al. Identification of e-MYC as a target of the APC pathway[J]. *Science*, 1998, 281(5382): 1509–1512.

\[^{[10]}\] Shuttman M, Zhurinsky J, Simcha I, et al. The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway[J]. *Proc Natl Acad Sci U S A*, 1999, 96(10): 5522–5527.

\[^{[11]}\] Li N, Lee K, Xi Y, et al. Phosphodiesterase 10A: a novel target for selective inhibition of colon tumor cell growth and β-catenin-dependent TCF transcriptional activity[J]. *Oncogene*, 2015, 34(12): 1499–1509.

\[^{[12]}\] Lee K, et al. β-catenin nuclear translocation in colorectal cancer cells is suppressed by PDE10A inhibition, cGMP elevation, and activation of PKG[J]. *Oncotarget*, 2015.

\[^{[13]}\] Koh TJ, Bulitta CJ, Fleming JV, et al. Gastrin is a target of the β-catenin/TCF-4 growth-signaling pathway in a model of intestinal polyposis[J]. *J Clin Invest*, 2000, 106(4): 533–539.

\[^{[14]}\] Kolligs FT, Nieman MT, Winer I, et al. ITF-2, a downstream target of the Wnt/TCF pathway, is activated in human cancers with β-catenin defects and promotes neoplastic transformation [J]. *Cancer Cell*, 2002, 1(2): 145–155.

\[^{[15]}\] Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer[J]. *Cell*, 1996, 87(2): 159–170.

\[^{[16]}\] Munemitsu S, Albert I, Souza B, et al. Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein[J]. *Proc Natl Acad Sci U S A*, 1995, 92(7): 3046–3050.

\[^{[17]}\] Shoemaker AR, Gould KA, Luongo C, et al. Studies of neoplasia in the Min mouse[J]. *Biochim Biophys Acta*, 1997, 1332(2): F25–F48.

\[^{[18]}\] Moser AR, Shoemaker AR, Connelly CS, et al. Homozygosity
for the Min allele of Apc results in disruption of mouse development prior to gastrulation[J]. *Dev Dyn*, 1995, 203(4): 422–433.

[19] Cooper HS, Chang WC, Coudry R, et al. Generation of a unique strain of multiple intestinal neoplasia (Apc(−/−Min−FCCC)) mice with significantly increased numbers of colorectal adenomas[J]. *Mol Carcinog*, 2005, 44(1): 31–41.

[20] Woo DK, Kim HS, Lee HS, et al. Altered expression and mutation of β-catenin gene in gastric carcinomas and cell lines [J]. *Int J Cancer*, 2001, 95(2): 108–113.

[21] Abraham SC, Nobukawa B, Giardiello FM, et al. Sporadic fundic gland polyps: common gastric polyps arising through activating mutations in the β-catenin gene[J]. *Am J Pathol*, 2001, 158(3): 1005–1010.

[22] Giles RH, van Es JH, Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer[J]. *Biochim Biophys Acta*, 2003, 1653 (1): 1–24.

[23] Björklund P, Lindberg D, Akerström G, et al. Stabilizing mutation of CTNNB1/beta-catenin and protein accumulation analyzed in a large series of parathyroid tumors of Swedish patients[J]. *Mol Cancer*, 2008, 7: 53.

[24] McCubrey JA, Steelman LS, Bertrand FE, et al. GSK-3 as potential target for therapeutic intervention in cancer[J]. *Oncotarget*, 2014, 5(10): 2881–2911.

[25] Chan TA. Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention[J]. *Lancet Oncol*, 2002, 3 (3): 166–174.

[26] Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis[J]. *N Engl J Med*, 1993, 328(18): 1313–1316.

[27] Beazer-Barclay Y, Levy DB, Moser AR, et al. Sulindac suppresses tumorigenesis in the Min mouse[J]. *Carcinogenesis*, 1996, 17(8): 1757–1760.

[28] Piazza GA, Alberts DS, Hixson LJ, et al. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels[J]. *Cancer Res*, 1997, 57 (14): 2909–2915.

[29] Strong HA, Warner NJ, Renwick AG, et al. Sulindac metabolism: the importance of an intact colon[J]. *Clin Pharmacol Ther*, 1985, 38(4): 387–393.

[30] Arber N, Kuwada S, Leshno M, et al., and the Exisulind Study Group. Sporadic adenomatous polyp regression with exisulind: a randomised, double blind, placebo controlled, dose-response study[J]. *Gut*, 2006, 55(3): 367–373.

[31] Thompson WJ, Piazza GA, Li H, et al. Exisulind induction of apoptosis involves guanosine 3′,5′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G-activation, and attenuated β-catenin[J]. *Cancer Res*, 2000, 60(13): 3338–3342.

[32] Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use[J]. *Pharmacol Rev*, 2006, 58(3): 488–520.

[33] Scott JD. Cyclic nucleotide-dependent protein kinases[J]. *Pharmacol Ther*, 1991, 50(1): 123–145.

[34] Zaccolo M, Movsesian MA. cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology[J]. *Circ Res*, 2007, 100(11): 1569–1578.

[35] White RE, Kryman JP, El-Mowafy AM, et al. cAMP-dependent vasodilators cross-activate the cGMP-dependent protein kinase to stimulate BK(Ca) channel activity in coronary artery smooth muscle cells[J]. *Circ Res*, 2000, 86(8): 897–905.

[36] Tinsley HN, Gary BD, Keeton AB, et al. Sulindac sulfone selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G[J]. *Mol Cancer Ther*, 2009, 8(12): 3331–3340.

[37] Tinsley HN, Gary BD, Keeton AB, et al. Inhibition of PDE5 by Sulindac Sulfide selectively induces apoptosis and attenuates oncogenic Wnt-Catenin-mediated transcription in human breast tumor cells[J]. *Cancer Prev Res (Phila. Pa.)*, 2011, 4(8): 1275–1284.

[38] Whitt JD, Li N, Tinsley HN, et al. A novel sulindac derivative that potently suppresses colon tumor cell growth by inhibiting cGMP phosphodiesterase and β-catenin transcriptional activity [J]. *Cancer Prev Res (Phila.)*, 2012, 5(6): 822–833.

[39] Saravani R, Karami-Tehrani F, Hashemi M, et al. Inhibition of phosphodiesterase 9 induces cGMP accumulation and apoptosis in human breast cancer cell lines, MCF-7 and MDA-MB-468[J]. *Cell Prolif.*, 2012, 45(3): 199–206.

[40] Bernard JJ, Lou YR, Peng QY, et al. PDE2 is a novel target for attenuating tumor formation in a mouse model of UVB-induced skin carcinogenesis[J]. *PLoS One*, 2014, 9(10): e109862.

[41] Zhang L, Murray F, Zahno A, et al. Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia[J]. *Proc Natl Acad Sci U S A.*, 2008, 105(49): 19532–19537.

[42] Kwon IK, Wang R, Thanaguru M, et al. PKG inhibits TCF signaling in colon cancer cells by blocking β-catenin expression and activating FOXO4[J]. *Oncogene*, 2010, 29(23): 3423–3434.

[43] Babykutty S, Subo P, Srinivas P, et al. Insidious role of nitric oxide in migration/invasion of colon cancer cells by upregulating MMP-2/9 via activation of cGMP-PKG-ERK signaling pathways[J]. *Clin Exp Metastasis*, 2012, 29(5): 471–492.

[44] Deguchi A, Thompson WJ, Weinstein IB. Activation of protein kinase G is sufficient to induce apoptosis and inhibit cell migration in colon cancer cells by blocking β-catenin expression and activating FOXO4[J]. *Oncogene*, 2010, 29(23): 3423–3434.

[45] Rahbi H, Narayan H, Jones DJL, et al. The uroguanylin system and human disease[J]. *Clin Sci (Lond)*, 2012, 123(12): 659–
Soh JW, Kazi JU, Li H, et al. Celecoxib-induced growth inhibition in SW480 colon cancer cells is associated with activation of protein kinase G[J]. *Mol Carcinog.*, 2008, 47(7): 519–525.

Deguchi A, Soh JW, Li H, et al. Vasodilator-stimulated phosphoprotein (VASP) phosphorylation provides a biomarker for the action of exisulind and related agents that activate protein kinase G[J]. *Mol Cancer Ther*, 2002, 1(10): 803–809.

Li N, Xi Y, Tinsley HN, et al. Sulindac selectively inhibits colon tumor cell growth by activating the cGMP/PKG pathway to suppress Wnt/β-catenin signaling[J]. *Mol Cancer Ther*, 2013, 12(9): 1848–1859.

Li N, Chen X, Zhu B, et al. Suppression of β-catenin/TCF transcriptional activity and colon tumor cell growth by dual inhibition of PDE5 and 10[J]. *Oncotarget*, 2015, 6(29): 27403–27415.

Lu W, Tinsley HN, Keeton A, et al. Suppression of Wnt/β-catenin signaling inhibits prostate cancer cell proliferation[J]. *Eur J Pharmacol*, 2009, 602(1): 8–14.

Lepourcelet M, Chen YN, France DS, et al. Small-molecule antagonists of the oncogenic Tcf/β-catenin protein complex[J]. *Cancer Cell*, 2004, 5(1): 91–102.

Guan H, Tan P, Xie L, et al. FOXO1 inhibits osteosarcoma oncogenesis via Wnt/β-catenin pathway suppression[J]. *Oncogenesis*, 2015, 4(9): e166.

**CLINICAL TRIAL REGISTRATION**

The *Journal* requires investigators to register their clinical trials in a public trials registry for publication of reports of clinical trials in the Journal. Information on requirements and acceptable registries is available at [https://clinicaltrials.gov](https://clinicaltrials.gov).